Balversa 4mg (Erdafitinib Tablet) 4mg

Balversa 4mg (erdafitinib) is a prescription tablet used for treating certain types of bladder cancer. This oral medication helps manage advanced urothelial carcinoma in patients with specific genetic mutations. Balversa 4mg provides targeted therapy for eligible adults under medical supervision.

Strength

4mg

Pack Size

28s

Storage

Ambient

Manufacturer / TM Owner

Janssen Products LP

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Balversa 4mg (erdafitinib) is used to treat adults with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. It is prescribed for patients whose cancer has a specific genetic mutation called FGFR3 or FGFR2. This medication is typically used when the cancer has progressed despite prior treatments. Balversa 4mg works by targeting abnormal signals in cancer cells.

Side Effects

Balversa 4mg (erdafitinib) may help slow the progression of bladder cancer in eligible patients. Common effects include changes in how the body processes certain nutrients, which may require dietary adjustments. Some patients report mild digestive changes or skin-related effects while taking this medication. Individual responses vary widely.

Precautions & Warnings

Balversa 4mg (erdafitinib) should be taken exactly as prescribed by a healthcare provider. Patients should discuss their full medical history, including eye problems or liver conditions, before starting treatment. Regular monitoring, including eye exams, may be recommended during therapy. Avoid grapefruit products unless approved by a doctor.

Avoid Interactions

Balversa 4mg (erdafitinib) may interact with other medications, including strong CYP3A4 inhibitors or inducers. Grapefruit and grapefruit juice can affect how the body processes this drug. Certain supplements or herbal products may also interact; always inform your healthcare provider about all medications being taken. Alcohol use should be discussed with a doctor.

Frequently Asked Questions

Balversa 4mg (erdafitinib) is used to treat advanced bladder cancer in adults with specific genetic mutations.

Balversa 4mg is an oral tablet taken once daily with or without food, as directed by a doctor.

Common effects may include digestive changes, skin effects, or changes in how the body processes nutrients.

Grapefruit products may interact with Balversa 4mg; consult your healthcare provider before consuming them.

Balversa 4mg is a targeted therapy, not a traditional chemotherapy medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.